Teva, University College London start brain imaging study to treat neurodegenerative diseases

Teva Pharmaceutical Industries and University College London (UCL) have started a brain-imaging study to uncover a new approach in neurodegenerative disease. The Pilot Longitudinal Study in Alzheimer's Disease of Central Markers of Microglial Activation (PADMMA) combines brain imaging with key biomarkers to identify the role of inflammation in neurodegenerative disease. The two-year study, which will be carried out in 20 patients, uses PET imaging to look at microglia cells in the central nervous system (CNS). Read more.